newsfilter
← Latest News
GlobeNewswire·

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering drops90% of patients maintained ≥20/25